FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385702743> ?p ?o ?g. }

• W4385702743 endingPage "e160928c" @default.
• W4385702743 startingPage "e160928c" @default.
• W4385702743 abstract "Background: Ven+Aza has shown efficacy in patients (pts) with AML ineligible for intensive chemotherapy (IC). In monocytic AML (mAML), ex vivo studies have shown that Ven may have reduced activity secondary to overexpression of MCL1 (Kuusanmaki, 2020; Kurtz, 2022) and clinical studies have suggested that M5 AML may be less sensitive to Ven+Aza (Pei, 2020). Aims: To report findings by AML differentiation status using French-American British (FAB) subtyping (M4, M5) and gene expression profiling (GEP) to define mAML from a post hoc analysis of Ven+ Aza in pts with IC ineligible mAML. Methods: Pts from the Phase 1b M14-358 (NCT02203773) and Phase 3 VIALE-A (NCT02993523) studies who received Ven+Aza were included. Two methods were used to define mAML: investigator-assessed FAB subtyping (M4, M5, non-M4/M5; n=197) or baseline GEP in pts with >30% AML blasts (n=153); 77 pts had both FAB and GEP data. For GEP, expression levels of genes associated with monocytic differentiation (CD14, ITGAM [CD11b], CD300e, and CR1 [CD35]) were used to classify pts as mAML (high) or non-mAML (low). Complete remission (CR)+CR with incomplete marrow recovery (CRi) rates and median overall survival (mOS) are reported. Results: Per FAB subtyping, 32, 24, and 141 pts had M4, M5, or non-M4/M5 AML, respectively. CR+CRi rates per FAB were 63% (95% CI, 45.2−77.1) for M4, 58% (38.8-75.5) for M5, and 71% (62.9-77.8) for non-M4/M5 AML. mOS was 12.4 mo (95% CI, 3.4-32.5), 16.8 mo (5.8-27.5), and 14.7 mo (10.7-22.3), respectively (Fig. A). Mutation analysis was performed for 24 pts with M4, 13 pts with M5, and 108 pts with non-M4/M5 AML; NPM1mut rates were 13%, 31%, and 14%, IDH1/2mut rates were 13%, 38%, and 30%, TP53mut rates were 25%, 0%, and 29%, and N/KRASmut rates were 33%, 31%, and 11%, respectively. Using GEP, 76 and 77 pts were categorized as mAML or non-mAML, respectively. Among FAB evaluable, 86% (6/7) with M5 and 85% (11/13) with M4 were identified as mAML. CR+CRi rates based on GEP were similar between mAML (62% [95% CI, 50.6-71.9]) vs non-mAML (69% [57.8-78.1]), as was mOS (14.7 mo [95% CI, 8.2-24.3] vs 15.2 mo [10.6-20.5]). In mAML vs non-mAML, NPM1mut rates were 15% vs 24%, IDH1/2mut rates were 27% vs 45%, TP53mut rates were 14% vs 15%, and N/KRASmut rates were 20% vs 11%, respectively. In the mAML group by GEP, 11 pts had NPM1mut and 63 pts had wild-type (WT) NPM1. CR+CRi rates (95% CI) were 64% (35.4-84.8) vs 60% (48-71.5) and mOS (95% CI) was 46.3 mo (3.4-not reached [NR]) vs 11.5 mo (6.7-22.3) for those with vs without NPM1mut mAML, respectively. In pts with N/KRASmut (n=15) vs WT N/KRAS (n=59) mAML, CR+CRi rates (95% CI) were 33% (15.2-58.3) vs 68% (55.1-78.3) and mOS (95% CI) was 3.4 mo (1.1-10.4) vs 19.4 mo (9.3-29.2), respectively (Fig. B). In the non-mAML group, 18 pts had NPM1mut and 56 pts had WT NPM1; CR+CRi rates (95% CI) were 72% (49.1-87.5) and 66% (53.0-77.1), respectively, and mOS (95% CI) was 12.5 mo (6.3-NE) and 14.1 mo (8.5-19.9), respectively. In pts with N/KRASmut (n=8) vs WT N/KRAS (n=66) non-mAML, CR+CRi rates (95% CI) were 75% (40.9-92.8) vs 67% (54.7-76.8), and mOS (95% CI) was 13 mo (0-27.5) vs 14 mo (10-21), respectively. Summary/Conclusion: Outcomes between pts with M4 or M5 AML vs non-M4/M5 AML, as well as mAML vs non-mAML, were overall similar. Differences in response and survival among patients with mAML was most closely linked to the presence or absence of prognostically relevant mutations, such as NPM1 and N/KRAS mutations.Keywords: Venetoclax, Acute myeloid leukemia, Genomics, Azacitidine" @default.
• W4385702743 created "2023-08-10" @default.
• W4385702743 creator A5010786159 @default.
• W4385702743 creator A5016368595 @default.
• W4385702743 creator A5018469890 @default.
• W4385702743 creator A5032549755 @default.
• W4385702743 creator A5056317446 @default.
• W4385702743 creator A5060702960 @default.
• W4385702743 creator A5066196706 @default.
• W4385702743 creator A5089772256 @default.
• W4385702743 creator A5091254943 @default.
• W4385702743 date "2023-08-01" @default.
• W4385702743 modified "2023-09-27" @default.
• W4385702743 title "P521: FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC AND MONOCYTIC-LIKE ACUTE MYELOID LEUKEMIA (AML), INCLUDING AML-M4 AND AML-M5, TREATED WITH VENETOCLAX (VEN) PLUS AZACITIDINE (AZA)" @default.
• W4385702743 doi "https://doi.org/10.1097/01.hs9.0000968992.16092.8c" @default.
• W4385702743 hasPublicationYear "2023" @default.
• W4385702743 type Work @default.
• W4385702743 citedByCount "0" @default.
• W4385702743 crossrefType "journal-article" @default.
• W4385702743 hasAuthorship W4385702743A5010786159 @default.
• W4385702743 hasAuthorship W4385702743A5016368595 @default.
• W4385702743 hasAuthorship W4385702743A5018469890 @default.
• W4385702743 hasAuthorship W4385702743A5032549755 @default.
• W4385702743 hasAuthorship W4385702743A5056317446 @default.
• W4385702743 hasAuthorship W4385702743A5060702960 @default.
• W4385702743 hasAuthorship W4385702743A5066196706 @default.
• W4385702743 hasAuthorship W4385702743A5089772256 @default.
• W4385702743 hasAuthorship W4385702743A5091254943 @default.
• W4385702743 hasBestOaLocation W43857027431 @default.
• W4385702743 hasConcept C104317684 @default.
• W4385702743 hasConcept C126322002 @default.
• W4385702743 hasConcept C143998085 @default.
• W4385702743 hasConcept C150194340 @default.
• W4385702743 hasConcept C190727270 @default.
• W4385702743 hasConcept C199360897 @default.
• W4385702743 hasConcept C2776239401 @default.
• W4385702743 hasConcept C2777938653 @default.
• W4385702743 hasConcept C2778461978 @default.
• W4385702743 hasConcept C2778729363 @default.
• W4385702743 hasConcept C2779675984 @default.
• W4385702743 hasConcept C38652104 @default.
• W4385702743 hasConcept C41008148 @default.
• W4385702743 hasConcept C55493867 @default.
• W4385702743 hasConcept C71924100 @default.
• W4385702743 hasConcept C83852419 @default.
• W4385702743 hasConcept C86803240 @default.
• W4385702743 hasConcept C9583187 @default.
• W4385702743 hasConceptScore W4385702743C104317684 @default.
• W4385702743 hasConceptScore W4385702743C126322002 @default.
• W4385702743 hasConceptScore W4385702743C143998085 @default.
• W4385702743 hasConceptScore W4385702743C150194340 @default.
• W4385702743 hasConceptScore W4385702743C190727270 @default.
• W4385702743 hasConceptScore W4385702743C199360897 @default.
• W4385702743 hasConceptScore W4385702743C2776239401 @default.
• W4385702743 hasConceptScore W4385702743C2777938653 @default.
• W4385702743 hasConceptScore W4385702743C2778461978 @default.
• W4385702743 hasConceptScore W4385702743C2778729363 @default.
• W4385702743 hasConceptScore W4385702743C2779675984 @default.
• W4385702743 hasConceptScore W4385702743C38652104 @default.
• W4385702743 hasConceptScore W4385702743C41008148 @default.
• W4385702743 hasConceptScore W4385702743C55493867 @default.
• W4385702743 hasConceptScore W4385702743C71924100 @default.
• W4385702743 hasConceptScore W4385702743C83852419 @default.
• W4385702743 hasConceptScore W4385702743C86803240 @default.
• W4385702743 hasConceptScore W4385702743C9583187 @default.
• W4385702743 hasIssue "S3" @default.
• W4385702743 hasLocation W43857027431 @default.
• W4385702743 hasLocation W43857027432 @default.
• W4385702743 hasOpenAccess W4385702743 @default.
• W4385702743 hasPrimaryLocation W43857027431 @default.
• W4385702743 hasRelatedWork W2889423049 @default.
• W4385702743 hasRelatedWork W2899472109 @default.
• W4385702743 hasRelatedWork W3048827006 @default.
• W4385702743 hasRelatedWork W4220981828 @default.
• W4385702743 hasRelatedWork W4283514695 @default.
• W4385702743 hasRelatedWork W4378175242 @default.
• W4385702743 hasRelatedWork W4386270784 @default.
• W4385702743 hasRelatedWork W4386277967 @default.
• W4385702743 hasRelatedWork W4386282105 @default.
• W4385702743 hasRelatedWork W4386282309 @default.
• W4385702743 hasVolume "7" @default.
• W4385702743 isParatext "false" @default.
• W4385702743 isRetracted "false" @default.
• W4385702743 workType "article" @default.